知镜 Cognispect · 医学文献与研究工作台

Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes.

Nguyen TK, Baxter AA, Bourchier C, Phan TK, Chan E, Poon IKH, Thomas SR, Hulett MD.
Clinical science (London, England : 1979) · 2026-08-01 · PMID 42290526

文献摘要

Diabetes mellitus accelerates the development of atherosclerotic cardiovascular disease. Heparanase, the sole enzyme responsible for cleaving heparan sulfates in the endothelial glycocalyx and subendothelial extracellular matrix, plays important pro-inflammatory roles in diabetes and atherosclerosis. However, the role of heparanase in diabetes-accelerated atherosclerosis is unknown. This study investigated the impact of heparanase gene-deficiency on atherosclerosis development in non-diabetic and streptozotocin (STZ)-treated, diabetic apolipoprotein E gene knockout (ApoE-/-) mice fed a normal chow diet for eight weeks. At the study endpoint, atherosclerotic lesion size and stability phenotype, along with blood glucose, serum lipid, and pro-inflammatory cytokine profiles were assessed. Compared to non-diabetic control ApoE-/- mice, STZ-treated, diabetic ApoE-/- mice exhibited significant increases in blood glucose, serum lipids, circulating MCP-1 and IL-6 levels, and the development of atherosclerotic lesion burden in the aortic sinus and aorta. While heparanase deficiency did not affect blood glucose or serum lipid levels, it significantly reduced the diabetes-dependent increase in circulating MCP-1 levels and diabetes-accelerated development of atherosclerotic lesions in the aortic sinus and aorta. Analysis of lesion composition and phenotype showed that diabetic ApoE-/- mice commonly exhibited advanced atherosclerotic lesions with well-developed necrotic cores, whereas diabetic heparanase-deficient ApoE-/- mice displayed early-stage atherosclerotic lesions, characterised by significantly smaller necrotic cores and increased collagen and smooth muscle cell content. The present study demonstrates that heparanase is a prominent pro-inflammatory protein driving the diabetes-accelerated formation of advanced atherosclerotic lesions with an unstable phenotype. Heparanase therefore represents a new therapeutic target for suppressing atherosclerotic cardiovascular disease in people with diabetes.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。